Lunbotinib

N/A

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug NameLunbotinib
Drug Alias Name富马酸仑博替尼KL-590586A-400EP-0031EP0031
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor RET inhibitors
TargetsTyrosine-protein kinase receptor RET
Therapy Area/IndicationsMedullary thyroid cancer (MTC)Solid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyGermany +[8] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesSichuan Kelun-Biotech Biopharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesEllipses Pharma LtdEllipses PharmaSichuan Kelun-Biotech Biopharmaceutical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsMedullary thyroid cancer (MTC)Solid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A